| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
Revenue  | 3,151 | 3,272 | 3,324 | 3,450 | 3,710 | 3,728 | 3,742 | 3,871 | 3,625 | 3,645 | 4,366 | 4,302 | 4,033 | 4,226 | 4,694 | 5,242 | 5,234 | 5,377 | 5,539 | 5,830 | 6,108 | 5,951 | 6,432 | 9,300 | 6,071 | 5,802 | 5,987 | 6,089 | 5,844 | 6,218 | 5,731 | 6,481 | 6,514 | 6,907 | 7,339 | 7,434 | 7,628 | 7,679 | 7,783 | 8,052 | 8,516 | 7,899 | 8,359 | 8,793 | 8,869 | 9,370 |
| Expenses | 2,506 | 2,574 | 2,586 | 2,688 | 2,885 | 2,878 | 2,847 | 3,011 | 2,920 | 2,845 | 3,319 | 3,311 | 3,261 | 3,539 | 3,792 | 4,208 | 4,271 | 4,311 | 4,473 | 4,701 | 4,862 | 4,679 | 5,071 | 5,011 | 4,735 | 4,502 | 4,766 | 4,993 | 5,002 | 5,303 | 4,950 | 5,453 | 5,477 | 5,772 | 5,846 | 5,753 | 6,042 | 5,949 | 6,230 | 6,401 | 6,622 | 6,265 | 6,608 | 6,938 | 7,103 | 7,311 |
| EBITDA | 645 | 698 | 738 | 762 | 825 | 851 | 895 | 860 | 704 | 800 | 1,047 | 992 | 772 | 687 | 902 | 1,033 | 963 | 1,066 | 1,066 | 1,130 | 1,247 | 1,271 | 1,361 | 4,290 | 1,335 | 1,300 | 1,220 | 1,096 | 842 | 914 | 781 | 1,027 | 1,037 | 1,135 | 1,493 | 1,681 | 1,585 | 1,730 | 1,553 | 1,652 | 1,894 | 1,634 | 1,752 | 1,855 | 1,766 | 2,059 |
| Operating Profit % | 20 % | 21 % | 22 % | 22 % | 21 % | 22 % | 23 % | 22 % | 18 % | 21 % | 24 % | 22 % | 18 % | 15 % | 19 % | 19 % | 18 % | 20 % | 19 % | 19 % | 20 % | 20 % | 20 % | 21 % | 21 % | 21 % | 19 % | 17 % | 14 % | 14 % | 13 % | 15 % | 14 % | 15 % | 18 % | 21 % | 19 % | 20 % | 19 % | 19 % | 21 % | 20 % | 20 % | 19 % | 19 % | 20 % |
| Depreciation | 85 | 89 | 93 | 99 | 111 | 106 | 110 | 111 | 100 | 131 | 132 | 138 | 157 | 155 | 164 | 163 | 187 | 241 | 243 | 250 | 232 | 256 | 257 | 277 | 266 | 280 | 294 | 299 | 254 | 280 | 298 | 321 | 346 | 327 | 418 | 423 | 354 | 404 | 382 | 419 | 444 | 406 | 429 | 465 | 479 | 487 |
| Interest | 21 | 31 | 68 | 9 | 25 | 21 | 18 | 14 | 14 | 17 | 17 | 19 | 25 | 30 | 35 | 48 | 50 | 50 | 41 | 37 | 32 | 21 | 16 | 20 | 18 | 13 | 10 | 16 | 9 | 15 | 25 | 45 | 56 | 57 | 68 | 76 | 89 | 111 | 113 | 119 | 115 | 98 | 95 | 93 | 98 | 102 |
| Profit Before Tax | 557 | 634 | 631 | 717 | 761 | 786 | 830 | 796 | 649 | 709 | 979 | 902 | 651 | 571 | 787 | 917 | 816 | 863 | 864 | 938 | 1,078 | 1,084 | 1,193 | 4,005 | 1,061 | 1,018 | 968 | 794 | 594 | 679 | 523 | 680 | 730 | 812 | 1,076 | 1,262 | 1,230 | 1,324 | 1,208 | 1,200 | 1,335 | 1,207 | 1,276 | 1,339 | 1,291 | 1,515 |
| Tax | 153 | 162 | 178 | 173 | 206 | 201 | 224 | 218 | 117 | 191 | 198 | 307 | 122 | 116 | 175 | 205 | 231 | 228 | 224 | 233 | 229 | 301 | 386 | 1,058 | 260 | 248 | 271 | 190 | 18 | 159 | 113 | 189 | 224 | 242 | 324 | 323 | 323 | 406 | 391 | 354 | 432 | 383 | 428 | 429 | 370 | 483 |
| Net Profit | 403 | 472 | 453 | 545 | 555 | 585 | 606 | 579 | 532 | 518 | 781 | 595 | 529 | 456 | 611 | 712 | 585 | 636 | 640 | 705 | 849 | 783 | 807 | 2,948 | 801 | 770 | 697 | 604 | 576 | 520 | 410 | 491 | 506 | 570 | 752 | 940 | 907 | 918 | 817 | 846 | 903 | 824 | 848 | 910 | 921 | 1,032 |
| EPS in ₹ | 13.84 | 16.18 | 7.77 | 9.32 | 9.49 | 9.99 | 10.41 | 9.88 | 9.10 | 8.85 | 13.33 | 10.16 | 9.02 | 7.78 | 10.44 | 12.15 | 9.99 | 10.85 | 10.92 | 12.04 | 14.50 | 13.32 | 13.78 | 50.31 | 13.67 | 13.14 | 11.89 | 10.32 | 9.84 | 8.88 | 6.99 | 8.38 | 8.64 | 9.74 | 12.83 | 16.04 | 15.51 | 15.69 | 14.00 | 14.56 | 15.56 | 14.20 | 14.61 | 15.67 | 15.86 | 17.86 |
Aurobindo Pharma
Aurobindo Pharma
1,660.00
-19.80
(-1.18%)
Market Cap
95,512.73 Cr
PE Ratio
25.98
Volume
4,38,757.00
Day High - Low
1,688.00 - 1,642.10
52W High-Low
1,717.00 - 1,061.30
Key Fundamentals
Market Cap
95,512.73 Cr
EPS
60.34
PE Ratio
25.98
PB Ratio
2.53
Book Value
658.53
EBITDA
7,337.80
Dividend Yield
0.24 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
9.25
Debt to Equity
0.23
Analyst Rating and Forecast
- By Refinitiv from27 analysts
Actual
Company News
View All News
Aurobindo Pharma gets USFDA nod for Beclomethasone HFA13 hrs ago
Aurobindo Pharma secured USFDA final approval for Beclomethasone Dipropionate HFA Inhalation Aerosol in 40 mcg and 80 mcg strengths, its first MDI product, in a US market worth $301 million.
Aurobindo Pharma completes acquisition of 100% stake in newly incorporated A1 Biochem USA Inc for $1 million to expand CRO services.
Aurobindo Pharma unit clears US FDA inspection cleanly4 days ago
Aurobindo Pharma's subsidiary Apitoria's Unit-IV API facility completed a US FDA inspection with no observations or issues raised, signalling regulatory compliance.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,835.00 | #1 4,40,277.97 | 36.48 | #1 61,673.90 | 12.69 | #1 11,565 | 26.53 | 33.19 | |
9,198.00 | 2,44,178.00 | 84.64 | 11,067.00 | 13.95 | 2,568 | 65.50 | 59.21 | |
4,850.00 | 1,84,478.41 | 87.77 | 13,886.20 | 20.34 | 2,138 | 3.28 | 44.26 | |
1,099.00 | 1,10,585.12 | 24.32 | 27,657.90 | 17.64 | 5,026 | -34.90 | 41.59 | |
1,351.00 | 1,09,139.90 | 32.86 | 29,044.60 | 2.24 | 3,870 | -39.18 | 32.08 | |
1,926.90 | 1,04,024.96 | 97.64 | 6,867.80 | 22.01 | 890 | #1 123.93 | 60.27 | |
1,145.00 | 95,569.61 | 30.44 | 35,058.60 | 3.90 | 4,158 | -69.10 | 41.23 | |
1,660.00 | #8 95,512.73 | #3 25.98 | #3 34,145.20 | #8 5.56 | #6 3,503 | #5 25.21 | 53.00 | |
2,063.20 | 94,336.22 | #1 17.27 | 29,038.90 | #1 26.75 | 5,356 | 16.00 | 24.64 | |
2,280.50 | 94,183.73 | 45.49 | 14,636.40 | 14.85 | 1,938 | 29.13 | 37.66 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
5.56 %
Net Income Growth
0.56 %
Cash Flow Change
40.81 %
ROE
-13.31 %
ROCE
-13.72 %
EBITDA Margin (Avg.)
-3.50 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 12,915 | 15,920 | 16,249 | 21,101 | 26,454 | 28,928 | 33,854 | 33,922 | 39,890 | 45,072 | 49,785 | 58,502 |
| Fixed Assets | 3,706 | 4,180 | 4,834 | 6,521 | 8,475 | 9,397 | 9,374 | 10,532 | 11,024 | 14,493 | 14,794 | 17,407 |
| Current Assets | 8,299 | 10,294 | 9,206 | 12,178 | 15,332 | 16,413 | 19,824 | 18,123 | 21,460 | 23,772 | 27,163 | 32,709 |
| Capital Work in Progress | 420 | 848 | 1,458 | 1,583 | 1,669 | 1,986 | 3,062 | 3,747 | 5,390 | 3,869 | 4,900 | 5,214 |
| Investments | 20 | 123 | 246 | 312 | 360 | 555 | 591 | 997 | 543 | 372 | 252 | 1,051 |
| Other Assets | 8,770 | 10,769 | 9,712 | 12,686 | 15,951 | 16,991 | 20,828 | 18,645 | 22,934 | 26,338 | 29,839 | 34,831 |
| Total Equity & Liabilities | 12,915 | 15,920 | 16,249 | 21,101 | 26,454 | 28,928 | 33,854 | 33,922 | 39,890 | 45,072 | 49,785 | 58,502 |
| Current Liabilities | 6,136 | 7,840 | 6,606 | 8,666 | 12,021 | 11,385 | 10,665 | 8,156 | 11,494 | 12,199 | 14,682 | 18,039 |
| Non Current Liabilities | 1,596 | 790 | 270 | 753 | 541 | 718 | 1,260 | 1,192 | 1,544 | 3,022 | 2,456 | 2,580 |
| Total Equity | 5,182 | 7,290 | 9,374 | 11,682 | 13,892 | 16,825 | 21,929 | 24,574 | 26,852 | 29,851 | 32,647 | 37,883 |
| Reserve & Surplus | 5,127 | 7,229 | 9,313 | 11,622 | 13,832 | 16,766 | 21,871 | 24,517 | 26,781 | 29,784 | 32,595 | 37,833 |
| Share Capital | 29 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 58 | 58 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Net Cash Flow | 313 | 340 | -424 | 892 | 666 | 871 | 2,561 | -1,164 | 230 | -1,007 | 2,178 | 1,628 |
| Investing Activities | -1,017 | -1,446 | -1,787 | -1,927 | -2,904 | -1,563 | 597 | -3,211 | -3,971 | -4,242 | -1,866 | -2,630 |
| Operating Activities | 1,237 | 1,420 | 3,279 | 1,955 | 1,651 | 4,381 | 3,329 | 5,017 | 2,387 | 2,435 | 3,925 | 5,526 |
| Financing Activities | 93 | 365 | -1,915 | 864 | 1,919 | -1,947 | -1,365 | -2,969 | 1,814 | 800 | 120 | -1,269 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| Promoter | 51.94 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.80 % | 51.82 % | 51.82 % | 51.82 % | 51.82 % | 51.82 % | 51.82 % | 51.82 % | 51.88 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 18.02 % | 16.73 % | 16.59 % | 16.29 % | 15.33 % | 14.37 % | 14.21 % | 13.94 % | 15.24 % | 16.38 % |
| DIIs | 10.99 % | 12.72 % | 13.82 % | 15.11 % | 15.83 % | 15.58 % | 16.23 % | 14.89 % | 15.08 % | 15.73 % | 17.94 % | 20.23 % | 23.28 % | 24.77 % | 25.13 % | 25.20 % | 26.23 % | 26.93 % | 27.60 % | 27.68 % | 25.87 % | 25.10 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 8.71 % | 8.54 % | 9.60 % | 8.99 % | 8.37 % | 8.80 % | 8.65 % | 9.42 % | 8.54 % | 7.01 % | 6.15 % | 5.64 % | 5.52 % | 5.47 % | 5.33 % | 5.52 % | 5.47 % | 5.67 % | 5.25 % | 5.36 % | 5.74 % | 5.36 % |
| Others | 28.36 % | 26.91 % | 24.74 % | 24.07 % | 23.97 % | 23.79 % | 23.29 % | 23.85 % | 24.54 % | 25.42 % | 24.07 % | 22.29 % | 1.36 % | 1.23 % | 1.13 % | 1.17 % | 1.15 % | 1.20 % | 1.13 % | 1.19 % | 1.34 % | 1.28 % |
| No of Share Holders | 2,32,634 | 2,43,315 | 3,29,940 | 3,41,568 | 3,38,639 | 3,59,684 | 3,58,459 | 3,69,828 | 3,43,617 | 2,93,214 | 2,59,638 | 2,41,944 | 2,44,575 | 2,38,622 | 2,48,488 | 2,57,962 | 2,69,323 | 2,72,208 | 2,47,662 | 2,36,859 | 2,41,298 | 2,39,073 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 3.2 | 2.5 | 2.5 | 3 | 4 | 9 | 7.5 | 4.5 | 0.00 | 4 |
| Dividend Yield (%) | 0.57 | 0.32 | 0.61 | 0.34 | 0.6 | 1.77 | 0.69 | 0.39 | 0.00 | 0.24 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 23 Feb 2021 |  Dividend | ₹ 1.50 /share | 22 Feb 2021 | 959.45 | 858.10 |
| 30 Aug 2021 | Dividend | ₹ 1.50 /share | 27 Aug 2021 | 856.50 | 709.95 |
| 18 Nov 2021 | Dividend | ₹ 1.50 /share | 17 Nov 2021 | 690.05 | 666.55 |
| 21 Feb 2022 | Dividend | ₹ 1.50 /share | 18 Feb 2022 | 650.05 | 656.80 |
| 07 Jun 2022 | Dividend | ₹ 4.50 /share | 06 Jun 2022 | 529.70 | 522.50 |
| 17 Feb 2023 | Dividend | ₹ 3.00 /share | 17 Feb 2023 | 445.05 | 479.90 |
| 20 Nov 2023 | Dividend | ₹ 3.00 /share | 20 Nov 2023 | 936.40 | 1,007.35 |
| 20 Feb 2024 | Dividend | ₹ 1.50 /share | 20 Feb 2024 | 1,002.00 | 1,040.50 |
| 05 Aug 2024 |  Buyback | 1460 | 30 Jul 2024 | 1,479.35 | 1,443.65 |
| 29 Aug 2024 |  Annual General Meeting | NA | 29 Aug 2024 | 1,404.35 | 1,564.20 |
| 09 Nov 2024 |  Quarterly Result Announcement | NA | 09 Nov 2024 | 1,396.00 | 1,327.55 |
| 06 Feb 2025 | Quarterly Result Announcement | NA | 06 Feb 2025 | 1,156.60 | 1,191.75 |
| 26 May 2025 | Quarterly Result Announcement | NA | 26 May 2025 | 1,216.90 | 1,197.10 |
| 04 Aug 2025 | Quarterly Result Announcement | NA | 04 Aug 2025 | 1,101.40 | 1,079.80 |
| 08 Aug 2025 | Dividend | ₹ 4.00 /share | 08 Aug 2025 | 1,079.80 | 1,069.60 |
| 10 Sept 2025 | Annual General Meeting | NA | 10 Sept 2025 | 1,052.90 | 1,044.05 |
| 05 Nov 2025 | Quarterly Result Announcement | NA | 05 Nov 2025 | 1,098.95 | 1,151.00 |
| 09 Feb 2026 | Quarterly Result Announcement | NA | 09 Feb 2026 | 1,150.55 | 1,191.00 |
| 23 Apr 2026 | Buyback | 1475 | 17 Apr 2026 | 1,422.60 | 1,421.20 |
| 21 May 2026 | Quarterly Result Announcement | NA | 21 May 2026 | 1,486.60 | 1,517.90 |
| 05 Aug 2026 | Quarterly Result Announcement | NA | 05 Aug 2026 | 1,532.00 | 1,583.80 |
| 27 Aug 2026 | Annual General Meeting | NA | 27 Aug 2026 | 1,549.20 | 1,622.00 |
Announcements
Completion Of US FDA Inspection At Unit-II Of Apitoria Pharma Private Limited A Wholly Owned Subsidiary Of The Company
8 hrs ago
8 hrs agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release14 hrs ago
14 hrs agoAnnouncement under Regulation 30 (LODR)-Acquisition3 days ago
3 days agoCompletion Of US FDA Inspection At Unit-IV Of Apitoria Pharma Private Limited A Wholly Owned Subsidiary Of The Company4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Newspaper PublicationSep 03, 2026
Sep 03, 2026Announcement under Regulation 30 (LODR)-AcquisitionSep 01, 2026
Sep 01, 2026Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)Aug 31, 2026
Aug 31, 2026Completion Of US FDA Inspection At Unit-VI Of Apitoria Pharma Private Limited A Wholly Owned Subsidiary Of The CompanyAug 28, 2026
Aug 28, 2026Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 28, 2026
Aug 28, 2026Shareholder Meeting / Postal Ballot-Outcome of AGMAug 27, 2026
Aug 27, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 25, 2026
Aug 25, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 25, 2026
Aug 25, 2026Completion Of US FDA Inspection At Lannett Company LLC A Wholly Owned Subsidiary Of Aurobindo Pharma USA Inc.Aug 24, 2026
Aug 24, 2026Completion Of US FDA Inspection At Auro Peptides Ltd A Subsidiary/Business Arm Of The Company.Aug 21, 2026
Aug 21, 2026Classification Of US FDA Inspection At Raleigh Plant North Carolina Owned By Aurolife Pharma LLC A Wholly Owned Step-Down Subsidiary Of The Company As Voluntary Action Indicated (VAI)Aug 17, 2026
Aug 17, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 14, 2026
Aug 14, 2026Unit I Of Eugia Pharma Specialities Ltd. Received A Warning Letter From US FDAAug 14, 2026
Aug 14, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 13, 2026
Aug 13, 2026Announcement under Regulation 30 (LODR)-AcquisitionAug 13, 2026
Aug 13, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 07, 2026
Aug 07, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 07, 2026
Aug 07, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 06, 2026
Aug 06, 2026Announcement under Regulation 30 (LODR)-RestructuringAug 05, 2026
Aug 05, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 05, 2026
Aug 05, 2026Announcement under Regulation 30 (LODR)-Investor PresentationAug 05, 2026
Aug 05, 2026Board Meeting Outcome for Outcome Of The Board Meeting Held On August 5 2026Aug 05, 2026
Aug 05, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 04, 2026
Aug 04, 2026Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 04, 2026
Aug 04, 2026Business Responsibility and Sustainability Reporting (BRSR)Aug 03, 2026
Aug 03, 2026Notice Of 39Th Annual General MeetingAug 03, 2026
Aug 03, 2026Reg. 34 (1) Annual Report.Aug 03, 2026
Aug 03, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 30, 2026
Jul 30, 2026Intimation Of 39Th Annual General Meeting Of Aurobindo Pharma Limited.Jul 29, 2026
Jul 29, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 29, 2026
Jul 29, 2026Board Meeting Intimation for Intimation Of Board Meeting.Jul 27, 2026
Jul 27, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 24, 2026
Jul 24, 2026Announcement under Regulation 30 (LODR)-AcquisitionJul 23, 2026
Jul 23, 2026ANVISA Approval For Curateq Biologics Biosimilars Manufacturing FacilityJul 21, 2026
Jul 21, 2026Announcement under Regulation 30 (LODR)-AcquisitionJul 10, 2026
Jul 10, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 02, 2026
Jul 02, 2026Completion Of Transfer Of CompanyS Domestic Branded Generic Pharmaceutical Formulations Products Business To Auropharm Limited A Wholly Owned Subsidiary Of The CompanyJul 02, 2026
Jul 02, 2026Announcement under Regulation 30 (LODR)-Updates on AcquisitionJun 30, 2026
Jun 30, 2026Completion Of US FDA Inspection At Auroactive Pharma Private Limited A Wholly Owned Subsidiary Of The Company.
Jun 27, 2026
Jun 27, 2026Announcement under Regulation 30 (LODR)-Updates on AcquisitionJun 25, 2026
Jun 25, 2026Closure of Trading WindowJun 25, 2026
Jun 25, 2026Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 57.04
ATR(14)
Less Volatile 37.77
STOCH(9,6)
Neutral 62.06
STOCH RSI(14)
Neutral 36.76
MACD(12,26)
Bullish 0.36
ADX(14)
Strong Trend 25.60
UO(9)
Bearish 62.43
ROC(12)
Uptrend And Accelerating 3.50
WillR(14)
Neutral -31.47
About Aurobindo Pharma
Aurobindo Pharma Limited (APL) is an Indian pharmaceutical company founded in 1986. It manufactures and markets active pharmaceutical ingredients, generic formulations, and branded pharmaceuticals globally. APL specializes in various therapeutic areas including antibiotics, antiretrovirals, cardiovascular, central nervous system, and gastroenterological products. The company operates 24 manufacturing plants worldwide and has...more
Website
Chairperson NameM R Kumar
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
